Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion. The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.
